Lexicon Pharma (LXRX) Tops Q3 EPS by 14c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.05 +0.49%
EPS Growth %: -50.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -50.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.35), $0.14 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $27.7 million versus the consensus estimate of $9.68 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Anthropic delays planned IPO from October to November - WSJ
- Can global equities keep rising? UBS sees these factors driving upside
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
